NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
A. Amatu,
A. Sartore-Bianchi,
S. Siena
|
8 |
2016 |
8
2016
|
Multiple primary tumours: challenges and approaches, a review
7 auth.
A. Vogt,
S. Schmid,
K. Heinimann,
H. Frick,
C. Herrmann,
T. Cerny,
...
A. Omlin
|
8 |
2017 |
8
2017
|
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
20 auth.
L. Albiges,
N. Tannir,
M. Burotto,
D. McDermott,
E. Plimack,
P. Barthélémy,
C. Porta,
T. Powles,
F. Donskov,
S. George,
...
C. Kollmannsberger,
H. Gurney,
M. Grimm,
Y. Tomita,
D. Castellano,
B. Rini,
T. Choueiri,
S. S. Saggi,
M. McHenry,
R. Motzer
|
8 |
2020 |
8
2020
|
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F. Morgillo,
C. D. Della Corte,
M. Fasano,
F. Ciardiello
|
8 |
2016 |
8
2016
|
Implementing TMB measurement in clinical practice: considerations on assay requirements
7 auth.
R. Büttner,
J. Longshore,
F. López-Rios,
S. Merkelbach-Bruse,
N. Normanno,
E. Rouleau,
...
F. Penault-Llorca
|
8 |
2019 |
8
2019
|
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
10 auth.
C. Granier,
E. de Guillebon,
C. Blanc,
H. Roussel,
C. Badoual,
Elia Colin,
...
A. Saldmann,
A. Gey,
S. Oudard,
E. Tartour
|
8 |
2017 |
8
2017
|
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
11 auth.
J. Arends,
F. Strasser,
S. Gonella,
T. Solheim,
C. Madeddu,
P. Ravasco,
...
L. Buonaccorso,
M. A. E. de van der Schueren,
C. Baldwin,
M. Chasen,
C. Ripamonti
|
8 |
2021 |
8
2021
|
Cardiotoxicity of immune checkpoint inhibitors
8 auth.
G. Varricchi,
M. Galdiero,
G. Marone,
Gjada Criscuolo,
M. Triassi,
D. Bonaduce,
...
G. Marone,
C. Tocchetti
|
8 |
2017 |
8
2017
|
Cancer and liver cirrhosis: implications on prognosis and management
M. Pinter,
M. Trauner,
M. Peck‐Radosavljevic,
W. Sieghart
|
7 |
2016 |
7
2016
|
Global cancer control: responding to the growing burden, rising costs and inequalities in access
27 auth.
G. Prager,
Sofia Braga,
B. Bystricky,
C. Qvortrup,
C. Criscitiello,
E. Esin,
G. Sonke,
Guillem Argilés Martínez,
J. Frenel,
M. Karamouzis,
M. Strijbos,
O. Yazıcı,
P. Bossi,
Susana Banerjee,
T. Troiani,
...
A. Eniu,
F. Ciardiello,
J. Tabernero,
C. Zielinski,
P. Casali,
F. Cardoso,
J. Douillard,
S. Jezdic,
K. Mcgregor,
G. Bricalli,
M. Vyas,
André Ilbawi
|
7 |
2018 |
7
2018
|
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
11 auth.
M. G. Geukes Foppen,
E. Rozeman,
Sandra van Wilpe,
C. Postma,
P. Snaebjornsson,
J. V. van Thienen,
...
M. V. van Leerdam,
M. M. van den Heuvel,
C. Blank,
J. V. van Dieren,
J. Haanen
|
7 |
2018 |
7
2018
|
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
13 auth.
M. Lambertini,
A. Toss,
A. Passaro,
C. Criscitiello,
C. Cremolini,
C. Cardone,
F. Loupakis,
G. Viscardi,
I. Meattini,
M. Dieci,
...
R. Ferrara,
R. Giusti,
M. Maio
|
7 |
2020 |
7
2020
|
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
18 auth.
M. Palmeri,
J. Mehnert,
A. Silk,
S. Jabbour,
S. Ganesan,
P. Popli,
G. Riedlinger,
R. Stephenson,
A.B. de Meritens,
A. Leiser,
...
T. Mayer,
N. Chan,
K. Spencer,
E. Girda,
J. Malhotra,
T. Chan,
V. Subbiah,
R. Groisberg
|
7 |
2021 |
7
2021
|
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
11 auth.
A. Berghoff,
S. Schur,
Lisa Füreder,
B. Gatterbauer,
K. Dieckmann,
G. Widhalm,
...
J. Hainfellner,
C. Zielinski,
P. Birner,
R. Bartsch,
M. Preusser
|
7 |
2016 |
7
2016
|
